Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older

BACKGROUND: Although older patients are at increased risk for venous thromboembolism (VTE), thromboprophylaxis is underused because of bleeding concerns. The MARINER trial evaluated whether rivaroxaban reduced symptomatic postdischarge VTE in acutely ill medical patients. OBJECTIVES: We hypothesized...

Descripción completa

Detalles Bibliográficos
Autores principales: Ageno, Walter, Lopes, Renato D., Goldin, Mark, Yusen, Roger D., Albers, Gregory W., Elliott, Gregory C., Halperin, Jonathan L., Hiatt, William R., Maynard, Gregory, Steg, Philippe Gabriel, Weitz, Jeffrey I., Suh, Eunyoung, Lu, Wentao, Barnathan, Elliot S., Raskob, Gary E., Spyropoulos, Alex C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
THROMBOSIS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292378/
https://www.ncbi.nlm.nih.gov/pubmed/34314574
http://dx.doi.org/10.1111/jth.15477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292378/
https://www.ncbi.nlm.nih.gov/pubmed/34314574
http://dx.doi.org/10.1111/jth.15477

Ejemplares similares